SV40轉(zhuǎn)化的非洲綠猴腎細胞C
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時間 2025/2/11 18:16:42
- 訪問次數(shù) 85
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時請說明是化工儀器網(wǎng)上看到的信息，謝謝!
SV40轉(zhuǎn)化的非洲綠猴腎細胞COS-7
| 種屬 | 猴 |
| 別稱 | Cos-7; COS7; Cos7; CV-1 in Origin Simian-7 |
| 組織來源 | 腎臟 |
| 疾病 | 轉(zhuǎn)化細胞系 |
| 傳代比例/細胞消化 | 1:2傳代 ，消化2-3分鐘 |
| 培養(yǎng)基配置 | DMEM培養(yǎng)基；10%胎牛血清；1%雙抗 |
| 簡介 | COS-7細胞源自CV-1細胞 ，經(jīng)帶有編碼野生型T抗原的起始失活突變的SV40轉(zhuǎn)染得到 |
| 形態(tài) | 成纖維細胞樣 |
| 生長特征 | 貼壁生長 |
| 倍增時間 | ~35-48h |
| 基因表達 | T antigen |
| 培養(yǎng)條件 | 氣相：空氣 ，95% ；二氧化碳 ，5%。 溫度：37攝氏度 ，培養(yǎng)箱濕度為70%-80%。 |
| 凍存條件 | 凍存液：90%FBS ，DMSO 10%, 或使用非程序凍存液：貨號JY-H040 |
| 保藏機構(gòu) | ATCC; CRL-1651 |
| 產(chǎn)品使用 | 于科學研究 ，不可作為動物或人類疾病的治療產(chǎn)品使用。 |
Results: The cohort had a mean age of 39 years and included patients with severe polytrauma. Technical success was achieved in 95% of cases, with no intraoperative deaths or need for open surgical conversion. Perioperative complications were minimal, and the reintervention rate was 5.3%. This study evaluates 10 years of clinical experience managing TAI with TEVAR. Long-term follow-up, with a median duration of 29 months, revealed no graft-related complications or secondary interventions. Imaging confirmed sustained graft integrity, and clinical outcomes were favorable.
Conclusion: TEVAR is a reliable and effective treatment for traumatic aortic injuries, offering excellent technical success rates and minimal perioperative and long-term complications. This study highlights TEVARs advantages in managing polytrauma patients and its role as a minimally invasive alternative to open surgery. Additionally, the findings emphasize the need for comprehensive long-term follow-up protocols. Future research should aim to address challenges related to device durability and the integration of advanced imaging techniques to further enhance patient outcomes and broaden the applicability of TEVAR in trauma care.
采購中心
化工儀器網(wǎng)